Collegium Q2 net revenue $199.9M (+6% YoY); GAAP loss $0.46; guidance cut on total revenue and EBITDA

COLLEGIUM PHARMACEUTICAL, INC

2026-Q2 EPS reported -$0.02 revenue$393,398,000

Q2 net revenue $199.9M, up 6% YoY; GAAP net loss $15.1M ($0.46 loss per share) vs prior year net income $12.0M.
Non-GAAP adjusted net income $75.4M ($1.92 adj EPS); Adjusted EBITDA $113.8M, up 8% YoY.
JORNAY PM revenue $46.1M (+41% YoY); AZSTARYS revenue $12.9M (partial quarter after May 12 acquisition close).
Full-year 2026 guidance: Product Revenues $825-855M (down from $865-895M); AZSTARYS raised to $65-75M; Adjusted EBITDA $445-470M (down from $475-500M).
Completed acquisition of AZSTARYS from Corium Therapeutics; board appointed Michael Donovan; HQ relocation to Boston planned for Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.